Answers are grounded in this paper and cite their sources.
The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant mCRC. Mitogen-activated protein kinase signaling was inhibited in all patients evaluated, but to a lesser degree than observed in BRAF-mutant melanoma with dabrafenib alone. PIK3CA mutations were identified in responding patients and thus do not preclude response to this regimen. Additional studies targeting the mitogen-activated protein kinase pathway in this disease are warranted.
No takes yet. Share an insight, caveat, or question.
Corcoran et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: